# Tecentriq Hybreza

NDC: 50242-933
Generic name: atezolizumab and hyaluronidase-tqjs
Labeler / Manufacturer: Genentech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: SUBCUTANEOUS
Marketing started: 20240912

FDA application: BLA761347

## Active ingredients

- ATEZOLIZUMAB: 1875 mg/15mL
- HYALURONIDASE (HUMAN RECOMBINANT): 30000 U/15mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"50242-933"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=50242-933
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f